Loading..

United Therapeutics Corporation (UTHR) Report Analysis

Corporate Events

Neutral

United Therapeutics Corporation Presents at 6th...

2022-08-27 02:36:00

United Therapeutics Corporation Presents at 6th Annual IPF Summit, Aug-29-2022 through Sep-01-2022. Venue: Boston, Massachusetts, United State...

Neutral

United Therapeutics Corporation Presents at Eur...

2022-08-24 10:00:00

United Therapeutics Corporation Presents at European Society of Cardiology (ESC) Congress 2022, Aug-26-2022 . Venue: Barcalona, Catalonia, Spain.

Neutral

United Therapeutics Corporation Presents at ERS...

2022-08-24 10:00:00

United Therapeutics Corporation Presents at ERS International Congress 2022, Sep-04-2022 . Venue: Bacelona, Spain.

Neutral

Hanson Wade Limited, 6th Annual IPF Summit, Aug...

2022-08-09 11:30:00

Hanson Wade Limited, 6th Annual IPF Summit, Aug 29, 2022 through Sep 01, 2022. Venue: Boston, Massachusetts, United States.

Neutral

United Therapeutics Corporation has filed a She...

2022-08-03 00:00:00

United Therapeutics Corporation has filed a Shelf Registration in the amount of $112.375 million. Security Name: Common Stock Securities O...

Neutral

United Therapeutics Corporation to Report Q2, 2...

2022-07-27 12:30:00

United Therapeutics Corporation announced that they will report Q2, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 03, 2022

Neutral

United Therapeutics Corporation, Q2 2022 Earnin...

2022-07-27 00:00:00

United Therapeutics Corporation, Q2 2022 Earnings Call, Aug 03, 2022

Neutral

European Respiratory Society, ERS International...

2022-07-11 12:05:00

European Respiratory Society, ERS International Congress 2022, Sep 04, 2022 through Sep 06, 2022. Venue: Bacelona, Spain.

Neutral

European Society Of Cardiology, European Societ...

2022-07-06 22:17:00

European Society Of Cardiology, European Society of Cardiology (ESC) Congress 2022, Aug 26, 2022 through Aug 29, 2022. Venue: Barcalona, Catal...

Negative

United Therapeutics Corporation(NasdaqGS:UTHR) ...

2022-06-24 00:00:00

United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 1000 Defensive Index

Negative

United Therapeutics Corporation(NasdaqGS:UTHR) ...

2022-06-24 00:00:00

United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 1000 Value-Defensive Index

Neutral

United Therapeutics Corporation Presents at Rea...

2022-06-13 18:52:00

United Therapeutics Corporation Presents at Realcomm Conference 2022, Jun-15-2022 01:30 PM. Venue: Orlando, Florida, United States. Speakers: ...

Neutral

United Therapeutics Corporation Presents at 202...

2022-06-03 20:30:00

United Therapeutics Corporation Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 11:00 AM. Venue: Marriott Marquis, New Yo...

Positive

United Therapeutics Corporation Announces FDA A...

2022-05-24 10:00:00

United Therapeutics Corporation announced that the U.S. Food and Drug Administration has approved Tyvaso DPI™ (treprostinil) inhalation powder...

Neutral

Realcomm Conference Group, LLC, Realcomm Confer...

2022-05-02 11:21:00

Realcomm Conference Group, LLC, Realcomm Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Orlando, Florida, United States.

Neutral

United Therapeutics Corporation - Shareholder/A...

2022-04-29 10:01:00

AGM

Neutral

United Therapeutics Corporation, Annual General...

2022-04-29 10:01:00

United Therapeutics Corporation, Annual General Meeting, Jun 27, 2022, at 10:30 US Eastern Standard Time. Agenda: To consider election of the ...

Neutral

United Therapeutics Corporation Presents at Ame...

2022-04-29 10:00:00

United Therapeutics Corporation Presents at American Thoracic Society 2022 International Conference, May-13-2022 through May-18-2022. Venue: S...

Neutral

United Therapeutics Corporation, Q1 2022 Earnin...

2022-04-27 13:18:00

United Therapeutics Corporation, Q1 2022 Earnings Call, May 04, 2022

Neutral

United Therapeutics Corporation to Report Q1, 2...

2022-04-27 10:00:00

United Therapeutics Corporation announced that they will report Q1, 2022 results Pre-Market on May 04, 2022

Positive

United Therapeutics Corporation Enters into Cre...

2022-04-01 10:14:00

On March 31, 2022, United Therapeutics Corporation entered into a Credit Agreement with certain of its subsidiaries party thereto, as guaranto...

Neutral

HMG Strategy, LLC, 2022 New York CIO Summit of ...

2022-03-03 20:59:00

HMG Strategy, LLC, 2022 New York CIO Summit of America, Apr 05, 2022. Venue: Pier 59, Chelsea Piers, Manhattan, New York, United States.

Neutral

United Therapeutics Corporation Presents at 202...

2022-03-03 20:59:00

United Therapeutics Corporation Presents at 2022 New York CIO Summit of America, Apr-05-2022 10:55 AM. Venue: Pier 59, Chelsea Piers, Manhatta...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Positive

United Therapeutics Corporation Receives Comple...

2021-12-27 11:31:00

United Therapeutics Corporation (“UT”) announced that it had received a Complete Response from the U.S. Food and Drug Administration (the “FDA...

Neutral

American Thoracic Society, Inc, American Thorac...

2021-11-13 09:53:00

American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022. Venue: San Francic...

Positive

3D Systems and United Therapeutics Corporation ...

2021-10-27 20:25:00

3D Systems announced an expansion of its joint development program with United Therapeutics Corporation. The development and license agreement...

Neutral

United Therapeutics Corporation, Q3 2021 Earnin...

2021-10-27 10:00:00

United Therapeutics Corporation, Q3 2021 Earnings Call, Nov 03, 2021

Neutral

United Therapeutics Corporation to Report Q3, 2...

2021-10-27 10:00:00

United Therapeutics Corporation announced that they will report Q3, 2021 results Pre-Market on Nov 03, 2021

Positive

United Therapeutics Corporation Details New Dat...

2021-10-21 10:00:00

United Therapeutics Corporation detailed the new clinical and real-world evidence on pulmonary arterial hypertension (PAH) and pulmonary hyper...

Neutral

MannKind Corporation and United Therapeutics Co...

2021-10-18 20:02:00

On October 16, 2021, MannKind Corporation (“MannKind”) and United Therapeutics Corporation (“United Therapeutics”) entered into an amendment (...

Positive

United Therapeutics Corporation Provides an Upd...

2021-10-18 10:00:00

United Therapeutics Corporation announced an update on the U.S. Food and Drug Administration (FDA) review of the new drug application (NDA) fo...

Positive

United Therapeutics to Present New Data At Ches...

2021-10-11 10:00:00

United Therapeutics Corporation announced new data on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interst...

Neutral

United Therapeutics Corporation Presents at 30t...

2021-10-01 10:34:00

United Therapeutics Corporation Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-08-2021 08:50 AM. Venue: Rancho Palos Verdes,...

Neutral

United Therapeutics Corporation Approves Amendm...

2021-10-01 10:01:00

United Therapeutics Corporation, at the Special Meeting of Shareholders held on September 30, 2021 the Company’s shareholders approved an amen...

Neutral

United Therapeutics Corporation Presents at 6th Annual IPF Summit, Aug-29-2022 through Sep-01-2022

2022-08-27 02:36:00

United Therapeutics Corporation Presents at 6th Annual IPF Summit, Aug-29-2022 through Sep-01-2022. Venue: Boston, Massachusetts, United States. Presentation Date & Speakers: Aug-31-2022, Peter Smith, Vice President – Product Development.

Neutral

United Therapeutics Corporation Presents at European Society of Cardiology (ESC) Congress 2022, Aug-26-2022

2022-08-24 10:00:00

United Therapeutics Corporation Presents at European Society of Cardiology (ESC) Congress 2022, Aug-26-2022 . Venue: Barcalona, Catalonia, Spain.

Neutral

United Therapeutics Corporation Presents at ERS International Congress 2022, Sep-04-2022

2022-08-24 10:00:00

United Therapeutics Corporation Presents at ERS International Congress 2022, Sep-04-2022 . Venue: Bacelona, Spain.

Neutral

Hanson Wade Limited, 6th Annual IPF Summit, Aug 29, 2022 through Sep 01, 2022

2022-08-09 11:30:00

Hanson Wade Limited, 6th Annual IPF Summit, Aug 29, 2022 through Sep 01, 2022. Venue: Boston, Massachusetts, United States.

Neutral

United Therapeutics Corporation has filed a Shelf Registration in the amount of $112.375 million.

2022-08-03 00:00:00

United Therapeutics Corporation has filed a Shelf Registration in the amount of $112.375 million. Security Name: Common Stock Securities Offered: 500,000 Transaction Features: ESOP Related Offering

Neutral

United Therapeutics Corporation to Report Q2, 2022 Results on Aug 03, 2022

2022-07-27 12:30:00

United Therapeutics Corporation announced that they will report Q2, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 03, 2022

Neutral

United Therapeutics Corporation, Q2 2022 Earnings Call, Aug 03, 2022

2022-07-27 00:00:00

United Therapeutics Corporation, Q2 2022 Earnings Call, Aug 03, 2022

Neutral

European Respiratory Society, ERS International Congress 2022, Sep 04, 2022 through Sep 06, 2022

2022-07-11 12:05:00

European Respiratory Society, ERS International Congress 2022, Sep 04, 2022 through Sep 06, 2022. Venue: Bacelona, Spain.

Neutral

European Society Of Cardiology, European Society of Cardiology (ESC) Congress 2022, Aug 26, 2022 through Aug 29, 2022

2022-07-06 22:17:00

European Society Of Cardiology, European Society of Cardiology (ESC) Congress 2022, Aug 26, 2022 through Aug 29, 2022. Venue: Barcalona, Catalonia, Spain.

Negative

United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 1000 Defensive Index

2022-06-24 00:00:00

United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 1000 Defensive Index

Negative

United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 1000 Value-Defensive Index

2022-06-24 00:00:00

United Therapeutics Corporation(NasdaqGS:UTHR) dropped from Russell 1000 Value-Defensive Index

Neutral

United Therapeutics Corporation Presents at Realcomm Conference 2022, Jun-15-2022 01:30 PM

2022-06-13 18:52:00

United Therapeutics Corporation Presents at Realcomm Conference 2022, Jun-15-2022 01:30 PM. Venue: Orlando, Florida, United States. Speakers: Thomas Kaufman.

Neutral

United Therapeutics Corporation Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 11:00 AM

2022-06-03 20:30:00

United Therapeutics Corporation Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 11:00 AM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: James C. Edgemond, CFO & Treasurer.

Positive

United Therapeutics Corporation Announces FDA Approval of Tyvaso DPI

2022-05-24 10:00:00

United Therapeutics Corporation announced that the U.S. Food and Drug Administration has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH and PH-ILD. PAH is life-threatening high blood pressure in the arteries of the lungs, affecting the ability of the heart and lungs to work properly. PAH affects an estimated 45,000 patients in the United States. Interstitial lung disease (ILD) is a group of conditions in which marked scarring occurs within the lungs. It is often complicated by pulmonary hypertension (PH; high blood pressure in the lungs), which furthers symptoms and decreases survival. PH is estimated to affect at least 15% of patients with early-stage ILD (approximately 30,000 PH-ILD patients in the United States) and may affect up to 86% of patients with more severe ILD. Tyvaso® (treprostinil) Inhalation Solution and Tyvaso DPI are the only therapies approved by the FDA to treat PH-ILD. FDA approval of the new drug application for Tyvaso DPI is supported by data from BREEZE, an open label study of 51 PAH patients on a stable regimen of Tyvaso Inhalation Solution who were transitioned to Tyvaso DPI. In subjects with PAH, transition from Tyvaso Inhalation Solution to Tyvaso DPI demonstrated safety and tolerance during the three-week treatment phase with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported outcomes. Top line data from BREEZE were issued in January 2021, efficacy data were presented in September 2021, long-term open-label safety data were published in April 2022, and additional long-term safety and efficacy data were presented in May 2022.

Neutral

Realcomm Conference Group, LLC, Realcomm Conference 2022, Jun 15, 2022 through Jun 16, 2022

2022-05-02 11:21:00

Realcomm Conference Group, LLC, Realcomm Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Orlando, Florida, United States.

Neutral

United Therapeutics Corporation - Shareholder/Analyst Call

2022-04-29 10:01:00

AGM

Neutral

United Therapeutics Corporation, Annual General Meeting, Jun 27, 2022

2022-04-29 10:01:00

United Therapeutics Corporation, Annual General Meeting, Jun 27, 2022, at 10:30 US Eastern Standard Time. Agenda: To consider election of the nine directors named in this Proxy Statement; to consider Advisory resolution to approve executive compensation; to consider approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan; to consider ratification of the appointment of Ernst & Young LLP as company independent registered public accounting firm for 2022.

Neutral

United Therapeutics Corporation Presents at American Thoracic Society 2022 International Conference, May-13-2022 through May-18-2022

2022-04-29 10:00:00

United Therapeutics Corporation Presents at American Thoracic Society 2022 International Conference, May-13-2022 through May-18-2022. Venue: San Francicso, California, United States. Presentation Date & Speakers: May-15-2022, Elizabeth S. Klings, M.D., Boston University School of Medicine, R James White, Ph.D., University of Rochester. May-16-2022, Aaron B Waxman, Brigham and Women’s Hospital, Boston.

Neutral

United Therapeutics Corporation, Q1 2022 Earnings Call, May 04, 2022

2022-04-27 13:18:00

United Therapeutics Corporation, Q1 2022 Earnings Call, May 04, 2022

Neutral

United Therapeutics Corporation to Report Q1, 2022 Results on May 04, 2022

2022-04-27 10:00:00

United Therapeutics Corporation announced that they will report Q1, 2022 results Pre-Market on May 04, 2022

Positive

United Therapeutics Corporation Enters into Credit Agreement

2022-04-01 10:14:00

On March 31, 2022, United Therapeutics Corporation entered into a Credit Agreement with certain of its subsidiaries party thereto, as guarantors, the lenders referred to therein, and Wells Fargo Bank, National Association, as administrative agent and as a swingline lender. The Credit Agreement provides for (i) an unsecured, revolving credit facility of up to $1.2 billion; and (ii) a second unsecured, revolving credit facility of up to $800 million. The facilities mature five years after the closing date of the Credit Agreement, subject to an ability of the lenders thereunder, or certain of the lenders thereunder, to elect to extend the maturity date of their commitments by one year following a request for such extension by the Company in accordance with the terms of the Credit Agreement, up to a maximum of two such extensions. As of March 31, 2022, Lung Biotechnology PBC is the only subsidiary of the Company required to be a Guarantor and guarantee the Company’s obligations under the Credit Agreement. From time to time, one or more additional subsidiaries of the Company may be required to guarantee the Company’s obligations under the Credit Agreement. At the Company’s option, the loan will bear interest at either an adjusted Term SOFR rate or a fluctuating base rate, in each case, plus an applicable margin that is determined on a quarterly basis based on the Company’s consolidated total leverage ratio (as calculated in accordance with the Credit Agreement). The proceeds of borrowings under the Credit Agreement are available to refinance certain existing indebtedness of the Company and its subsidiaries and/or for working capital and other general corporate purposes. Upon closing of the Credit Agreement on March 31, 2022, the Company borrowed $800.0 million under the Credit Agreement, and used the funds to repay outstanding indebtedness under the 2018 Credit Agreement discussed under Item 1.02 below. The Credit Agreement also contains customary affirmative and negative covenants that, among other things, limit the ability of the Company and its subsidiaries to: (a) incur indebtedness; (b) grant liens; (c) enter into a merger, consolidation, or amalgamation; (d) liquidate, wind up, or dissolve; or (e) sell all or substantially all of the property, business, or assets of the Company and its subsidiaries taken as a whole. In addition, as of the last day of each fiscal quarter, the Company must not permit (i) a consolidated ratio of total indebtedness to EBITDA to be greater than 3.00 to 1.00 (which ratio may, upon consummation of certain qualifying acquisitions, be increased to 3.50 to 1.00 for four fiscal quarters following such acquisition); and (ii) its consolidated interest coverage ratio to be less than 3.00 to 1.00, in each case calculated in accordance with the Credit Agreement. The Credit Agreement contains customary events of default, including a change of control. Upon the occurrence and continuation of an event of default, all amounts due under the Credit Agreement and the other loan documents become (in the case of a bankruptcy event), or may become (in the case of all other events of default and at the option of the lenders), immediately due and payable.

Neutral

HMG Strategy, LLC, 2022 New York CIO Summit of America, Apr 05, 2022

2022-03-03 20:59:00

HMG Strategy, LLC, 2022 New York CIO Summit of America, Apr 05, 2022. Venue: Pier 59, Chelsea Piers, Manhattan, New York, United States.

Neutral

United Therapeutics Corporation Presents at 2022 New York CIO Summit of America, Apr-05-2022 10:55 AM

2022-03-03 20:59:00

United Therapeutics Corporation Presents at 2022 New York CIO Summit of America, Apr-05-2022 10:55 AM. Venue: Pier 59, Chelsea Piers, Manhattan, New York, United States. Speakers: Shola Oyewole, Vice President of Digital Innovation.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Positive

United Therapeutics Corporation Receives Complete Response from the U.S. Food and Drug Administration

2021-12-27 11:31:00

United Therapeutics Corporation (“UT”) announced that it had received a Complete Response from the U.S. Food and Drug Administration (the “FDA”) concerning UT’s new drug application (“NDA”) for Tyvaso DPI™. On December 27, 2021, UT disclosed that it had resubmitted the NDA to the FDA.

Neutral

American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022

2021-11-13 09:53:00

American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022. Venue: San Francicso, California, United States.

Positive

3D Systems and United Therapeutics Corporation Announce Expansion of Bioprinting Program

2021-10-27 20:25:00

3D Systems announced an expansion of its joint development program with United Therapeutics Corporation. The development and license agreement, first established in 2017, combines the 3D printing expertise of 3D Systems, with the regenerative medicine and organ manufacturing expertise of United Therapeutics (UT). To date, the program has had a strong, singular focus on developing the capability to print scaffolds for human lungs using a process call Print to Perfusion™. This 3D printed scaffold would then be cellularized using cells derived from the recipient patient’s own body, to create personalized human lungs. 3D Systems has focused primarily on establishing the printing technology to produce scaffolds meeting the extreme precision and resolution requirements for a functional human lung and to do so in a manner that yields the physical, mechanical, and biocompatibility performance to influence cell behavior and reproduction required for extended use in the human body. The goal of the program is to establish an unlimited supply of human lungs, requiring no immunosuppression, allowing all patients with end-stage lung disease to receive transplants which will enable them to enjoy long and active lives. Based upon the progress made toward this goal, the program is now being expanded to include two additional human organs, with support now designated through 2025.

Neutral

United Therapeutics Corporation, Q3 2021 Earnings Call, Nov 03, 2021

2021-10-27 10:00:00

United Therapeutics Corporation, Q3 2021 Earnings Call, Nov 03, 2021

Neutral

United Therapeutics Corporation to Report Q3, 2021 Results on Nov 03, 2021

2021-10-27 10:00:00

United Therapeutics Corporation announced that they will report Q3, 2021 results Pre-Market on Nov 03, 2021

Positive

United Therapeutics Corporation Details New Data Presented at Chest Annual Meeting 2021

2021-10-21 10:00:00

United Therapeutics Corporation detailed the new clinical and real-world evidence on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) presented at CHEST 2021, the annual meeting of the American College of Chest Physicians. United Therapeutics and its collaborators presented 10 abstracts across a broad range of studies in PAH and PH-ILD, including pharmacokinetic (PK) data from the BREEZE study of Tyvaso DPI.  Tyvaso DPI BREEZE pharmacokinetic data demonstrate similar exposure as Tyvaso: The CHEST meeting featured a poster detailing data from the BREEZE study of Tyvaso DPI in patients with PAH. New PK data presented at CHEST 2021 demonstrated that systemic exposure between Tyvaso DPI and Tyvaso was similar; in addition, lower variability in PK parameters were observed in Tyvaso DPI when compared with Tyvaso. PK data from a separate healthy volunteer study of Tyvaso DPI will be presented at a future scientific forum. The BREEZE study enrolled 51 subjects on a stable regimen of Tyvaso who were transitioned to Tyvaso DPI at a corresponding treprostinil dose. The primary objective of the study was to evaluate the safety and tolerability of Tyvaso DPI during a three-week treatment phase in PAH patients previously treated with Tyvaso Inhalation Solution. Secondary objectives of the study included changes in six-minute walk distance (6WMD), device preference and satisfaction as evaluated through the Preference Questionnaire for Inhaled Treprostinil Devices, and patient-reported PAH symptoms and impact. Top line data showing the BREEZE study met its primary objective were released in January 2021, and detailed data on the primary and secondary objectives were presented in September 2021. United Therapeutics abstracts presented at CHEST 2021 included: Tyvaso abstracts: BREEZE: Clinical Outcomes and Pharmacokinetics (PK) of Treprostinil Inhalation Powder (Tyvaso DPI) Shelley Shapiro, MD; Leslie Spikes, MD; Ricardo Restrepo, MD; Joanna Joly, MD; Trushil Shah, MD; Jason Scoggin; Lisa Edwards, PhD; Peter Smith, PharmD; Melissa Miceli, PharmD. Inhaled treprostinil is currently delivered via a handheld ultrasonic nebulizer (Tyvaso Inhalation System). A dry powder formulation of treprostinil and a small, portable, inhaler (Tyvaso DPI) is in development for PAH. In patients with PAH, transition from Tyvaso to Tyvaso DPI was well-tolerated with significant improvements in 6MWD, device preference and satisfaction, and patient reported outcomes. Despite a 33% higher peak serum concentration (Cmax) observed for Tyvaso DPI vs. Tyvaso, the adverse event profiles were similar. Between-subject variability for area under the curve (AUC) and Cmax parameters was similar within treatment.  Dose-Response Analysis of Inhaled Treprostinil in Pulmonary Hypertension Associated with Interstitial Lung Disease and Its Effects on Clinical Worsening. Victor Tapson, MD; Steven Nathan, MD, PhD; Micah Fisher, MD; H. James Ford, MD; James Gagermeier, MD; Joseph Parambil, MD; Amresh Raina, MD; Dianne Zwicke, MD; Alicia Gerke, MD; Eric Shen, PharmD; Dasum Lee, MS; Youlan Rao, PhD; Aaron Waxman, MD. In a post-hoc analysis of patients with PH-ILD in the INCREASE trial, patients were divided into two dose groups, less than nine breaths per session and nine breaths per session and above. The higher doses of inhaled treprostinil were associated with a lower risk of clinical worsening. These results underscore the importance of inhaled treprostinil dose titration in the context of adverse event management for patients with PH-ILD. The Impact of Hemodynamic Parameters on Inhaled Treprostinil Treatment Response – A Subgroup Analysis from the INCREASE Trial. Aaron Waxman, MD, PhD; Victor Tapson, MD; Reda Girgis, MD; James Runo, MD; Remzi Bag, MD; Arunabh Talwar, MD; Peter Smith, PharmD; Dana Johnson, PhD; Christine Park, PharmD; Steven Nathan, MD. This INCREASE post-hoc analysis evaluated the treatment effect of inhaled treprostinil on 6MWD and forced vital capacity (FVC) as a function of baseline hemodynamics in participants with PH-ILD. PH-ILD patients with higher pulmonary vascular resistance (PVR) and/or mean pulmonary artery pressure (mPAP) had a greater response to treatment. This analysis suggests higher PVR and mPAP reflect progressive pulmonary vascular remodeling and demonstrates the importance of considering pulmonary hemodynamics when treating patients with PH-ILD. Healthcare Resource Utilization and Treatment Patterns Before and After Initiation of Inhaled Treprostinil. Charles Burger, MD, FCCP; Christine Park, PharmD; Peter Classi, MSc, MBA; Andrew Nelsen, PharmD; Benjamin Wu, PharmD. In this retrospective analysis of real-world data, inhaled treprostinil was effective in reducing hospitalization, a known risk factor for poor outcomes. The benefit remained substantial even in patients on prior dual background therapy with an endothelin receptor antagonist and phosphodiesterase-5 inhibitor or soluble guanylate cyclase stimulator. Burden of Illness in Patients with Pulmonary Hypertension due to Interstitial Lung Disease: A Real-World Analysis Using US Claims Data. Gustavo Heresi, MD; Howard Castillo, NP-C; Henry Lee, PharmD; Peter Classi, MSc, MBA; Dana Stafkey-Mailey, PharmD, PhD; Kellie D. Morland, PharmD; Margaret Sketch, MPH, PharmD; Alexander Kantorovich, PharmD; Benjamin Wu, PharmD; Bonnie Dean, PhD. A retrospective cohort study of patients with PH-ILD was conducted using research databases to characterize healthcare resource utilization and costs associated with PH-ILD. Patients with PH-ILD have significantly increased utilization of healthcare resources, including inpatient admissions, and costs, following an initial diagnosis of pulmonary hypertension.

Neutral

MannKind Corporation and United Therapeutics Corporation Enter into an Amendment to the Commercial Supply Agreement

2021-10-18 20:02:00

On October 16, 2021, MannKind Corporation (“MannKind”) and United Therapeutics Corporation (“United Therapeutics”) entered into an amendment (the “Amendment”) to the commercial supply agreement, dated August 12, 2021, by and between MannKind and United Therapeutics (the “Supply Agreement”) to, among other things, extend the term of the Supply Agreement and amend the non-renewal notification periods. Under the amended Supply Agreement, unless earlier terminated, the term of the Supply Agreement continues until December 31, 2031 and is thereafter renewed automatically for additional, successive two-year terms unless (i) United Therapeutics provides notice to MannKind at least 24 months in advance of such renewal that United Therapeutics does not wish to renew the Supply Agreement or (ii) MannKind provides notice to United Therapeutics at least 48 months in advance of such renewal that MannKind does not wish to renew the Supply Agreement.

Positive

United Therapeutics Corporation Provides an Update on the Progress of the Tyvaso DPI™ New Drug Application

2021-10-18 10:00:00

United Therapeutics Corporation announced an update on the U.S. Food and Drug Administration (FDA) review of the new drug application (NDA) for Tyvaso DPI™, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), to improve exercise capacity. On October 15, 2021, the FDA issued a complete response declining to approve the NDA at this time. The FDA's letter noted only a single deficiency preventing approval of Tyvaso DPI, related to an open inspection issue at a third-party facility that performs analytical testing of treprostinil drug substance. In addition, the FDA did not cite any deficiencies or issues related to operations performed at the MannKind Corporation facility for manufacture, testing, and packaging of finished Tyvaso DPI, including its associated device. All other requests from the agency have been addressed. The draft labeling for Tyvaso DPI, as revised by FDA, includes the same indications as Tyvaso® (treprostinil) Inhalation Solution for PAH and PH-ILD, to improve exercise ability, and does not contain any contraindications or a boxed warning. The complete response also notes, but does not cite as a deficiency, that the FDA has not yet completed its review of a Citizen's Petition submitted to FDA in July 2021 concerning the safety of an excipient in Tyvaso DPI. TYVASO (treprostinil) is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities. While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration. Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%).

Positive

United Therapeutics to Present New Data At Chest Annual Meeting 2021

2021-10-11 10:00:00

United Therapeutics Corporation announced new data on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented as posters at CHEST 2021.United Therapeutics and its collaborators are presenting a total of 10 abstracts across a broad range of studies in PAH and PH-ILD, including pharmacokinetic (PK) data from the BREEZE study of Tyvaso DPI™. The CHEST meeting will feature a poster detailing PK data from the BREEZE study of Tyvaso DPI in patients with PAH. The BREEZE study enrolled 51 subjects on a stable regimen of Tyvaso who were transitioned to Tyvaso DPI at a corresponding treprostinil dose. The primary objective of the study was to evaluate the safety and tolerability of Tyvaso DPI during a three-week treatment phase in PAH patients previously treated with Tyvaso Inhalation Solution. Secondary objectives of the study included changes in six-minute walk distance, device preference and satisfaction as evaluated through the Preference Questionnaire for Inhaled Treprostinil Devices, and patient-reported PAH symptoms and impact. Top line data showing the BREEZE study met its primary objective were released in January 2021, and detailed data on the primary and secondary objectives were presented in September 2021. PK data from a healthy volunteer study of Tyvaso DPI will be presented at a future scientific forum. Other Tyvaso posters will detail subgroup data on dose response and hemodynamics collected during the INCREASE study of Tyvaso Inhalation Solution in patients with PH-ILD. Top line results from the INCREASE study were issued in February 2020 and additional data were issued in June 2020 and January 2021. Key Orenitram® posters include real world interim data from the ADAPT registry of Orenitram patients and an analysis of U.S. medical claims for Orenitram and selexipag patients one year into treatment. BREEZE: Clinical Outcomes and Pharmacokinetics (PK) of Treprostinil Inhalation Powder (Tyvaso DPI). Dose-response Analysis of Inhaled Treprostinil in Pulmonary Hypertension Associated with Interstitial Lung Disease and Its Effects on Clinical Worsening. The Impact of Hemodynamic Parameters on Inhaled Treprostinil Treatment Response – A Subgroup Analysis from the INCREASE Trial. Healthcare Resource Utilization and Treatment Patterns Before and After Initiation of Inhaled Treprostinil. Burden of Illness in Patients with Pulmonary Hypertension due to Interstitial Lung Disease: A Real-World Analysis Using US Claims Data. Comparison of Effects of Inhaled Treprostinil on Lung Function in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease and Pulmonary Arterial Hypertension. Screening for Pulmonary Hypertension in Patients with Interstitial Lung Disease: Recommendations from a Delphi Consensus Panel. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

Neutral

United Therapeutics Corporation Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-08-2021 08:50 AM

2021-10-01 10:34:00

United Therapeutics Corporation Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-08-2021 08:50 AM. Venue: Rancho Palos Verdes, California, United States. Speakers: Michael I. Benkowitz, President & COO.

Neutral

United Therapeutics Corporation Approves Amendment to Company’s Restated Certificate of Incorporation

2021-10-01 10:01:00

United Therapeutics Corporation, at the Special Meeting of Shareholders held on September 30, 2021 the Company’s shareholders approved an amendment to the Company’s Restated Certificate of Incorporation. The changes to the Certificate of Incorporation consist of the following: Adding language stating that the Company is a public benefit corporation; and Adding language to the Company’s statement of business purpose identifying the specific public benefits to be promoted by the Company.

Fundamental Summary

According to their recent financial report, which was published on 2022-05-04, United Therapeutics had several impressive financial metrics that should make them more attractive than their peers going forward. Their growth, value, and income factors indicate a well-executed and balanced strategy, which is generating exciting growth. We expect that this positive performance will continue in the coming months, and anticipate that United Therapeutics will maintain good momentum even in a challenging environment. Therefore, they earned a total score of 85 out of 100 and a BUY recommendation.

United Therapeutics reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 466.9 million compared to USD 446.5 million a year ago. Net income was USD 116 million compared to USD 172.6 million a year ago. Basic earnings per share from continuing operations was USD 2.56 compared to USD 3.85 a year ago. Diluted earnings per share from continuing operations was USD 2.41 compared to USD 3.65 a year ago.For the six months, revenue was USD 928.8 million compared to USD 825.6 million a year ago. Net income was USD 355.9 million compared to USD 200.9 million a year ago. Basic earnings per share from continuing operations was USD 7.86 compared to USD 4.49 a year ago. Diluted earnings per share from continuing operations was USD 7.43 compared to USD 4.28 a year ago.

Business Description

United Therapeutics, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Sector Overview

United Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. United Therapeutics's industry and sector affiliation are expected to positively boost their relative likelihood to overperform the market looking forward, as they should benefit significantly from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 5.4B 3.7% 76
Liabilities 1.2B -2.2% 62
Price to Book 1.9 -21.0% 74
Cash & Equivalents 813.3M -9.1% 59
Equity 4.2B 5.5% 52
EBITDA 962.8M 30.0% 92
Total Revenues 1.8B 4.9% 56
Parameter Value Change Score
Return on Equity 18.0 39.4% 53
Net Cashflow -19.0M -112.2% 93
Capital Expenditure -123.7M -2.4% 67
Asset Turnover 0.4 2.6% 82
Free Cashflow Per Share 14.9 40.6% 92
* All values are TTM

The below chart reflects United Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While United Therapeutics's peer average final assessment score stands on 64, United Therapeutics's score is 85.

  •  UTHR
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 120.9B 80 78 76
Buy
81
81 0 1
Gilead Sciences, Inc. 78.5B 97 75 71
Strong Buy
88
88 1 1
Regeneron Pharmaceuticals, Inc. 74.3B 90 67 70
Buy
79
79 2 1
Vertex Pharmaceuticals Incorporated 73.0B 86 78 79
Buy
86
86 3 1
Biogen Inc. 28.7B 99 74 60
Buy
84
84 4 1
Seagen Inc. 25.0B 75 60 74
Hold
67
67 5 1
BioMarin Pharmaceutical Inc. 15.5B 82 88 63
Buy
83
83 6 1
Incyte Corporation 14.8B 81 80 77
Buy
83
83 7 1
Neurocrine Biosciences, Inc. 9.7B 90 60 89
Buy
83
83 8 1
Sarepta Therapeutics, Inc. 9.5B 70 54 81
Hold
64
64 9 1
Ionis Pharmaceuticals, Inc. 6.0B 72 58 93
Hold
72
72 10 1
Exelixis, Inc. 5.1B 66 64 65
Hold
60
60 11 1
Cytokinetics, Incorporated 4.6B 70 76 67
Hold
71
71 12 1
Mirati Therapeutics, Inc. 3.8B 63 65 71
Hold
61
61 13 1
Alkermes plc 3.6B 75 62 63
Hold
64
64 14 1
Arrowhead Pharmaceuticals, Inc. 3.3B 71 64 44
Underperform
54
54 15 1
Insmed Incorporated 2.6B 58 58 75
Underperform
56
56 16 1
BioCryst Pharmaceuticals, Inc. 2.3B 68 63 81
Hold
67
67 17 1
Ironwood Pharmaceuticals, Inc. 1.6B 77 76 78
Buy
79
79 18 1
Novavax, Inc. 1.6B 50 62 49
Underperform
43
43 19 1
Myriad Genetics, Inc. 1.5B 56 62 54
Underperform
48
48 20 1
FibroGen, Inc. 1.2B 69 85 71
Hold
77
77 21 1
Enanta Pharmaceuticals, Inc. 1.1B 60 84 74
Hold
71
71 22 1
ImmunoGen, Inc. 1.0B 64 64 63
Underperform
58
58 23 1
Geron Corporation 865.2M 92 79 51
Buy
79
79 24 1
Lexicon Pharmaceuticals, Inc. 469.0M 47 77 73
Underperform
59
59 25 1
Inovio Pharmaceuticals, Inc. 438.9M 62 57 72
Underperform
56
56 26 1
bluebird bio, Inc. 420.3M 44 73 86
Hold
60
60 27 1
Anika Therapeutics, Inc. 345.0M 63 59 69
Underperform
57
57 28 1
Rigel Pharmaceuticals, Inc. 198.8M 71 69 73
Hold
68
68 29 1
Nabi Biopharmaceuticals Inc. 47.5M 61 86 72
Hold
72
72 30 1
Acorda Therapeutics, Inc. 7.1M 49 85 64
Underperform
57
57 31 1
Exact Sciences Corporation 5.7B 52 66 52
Underperform
47
47 32 1
Abgenix Inc. 2.1B 66 46 57
Underperform
44
44 33 1
Ligand Pharmaceuticals Incorporated 1.4B 71 71 57
Hold
64
64 34 1
Avid Bioservices, Inc. 1.1B 75 60 78
Hold
69
69 35 1
CTI BioPharma Corp. 660.0M 69 72 82
Hold
73
73 36 1
Heron Therapeutics, Inc. 477.4M 55 72 86
Hold
67
67 37 1
Organogenesis Holdings Inc. 421.5M 74 72 58
Hold
66
66 38 1
Silence Therapeutics plc 285.3M 73 64 80
Hold
71
71 39 1
XOMA Corporation 196.4M 73 53 81
Hold
65
65 40 1
Lineage Cell Therapeutics, Inc. 193.5M 67 73 69
Hold
66
66 41 1
StemCells Inc. 187.3M 60 89 90
Hold
75
75 42 1
Anixa Biosciences, Inc. 162.5M 70 85 66
Hold
72
72 43 1
CEL-SCI Corporation 150.9M 61 80 72
Hold
66
66 44 1
eXegenics Inc. 129.4M 54 56 77
Underperform
60
60 45 1
iBio, Inc. 69.7M 65 51 92
Hold
61
61 46 1
Trimeris Inc 68.8M 81 57 83
Hold
76
76 47 1
Curis, Inc. 64.3M 67 54 74
Underperform
59
59 48 1
ImmuCell Corporation 58.6M 72 43 74
Underperform
59
59 49 1
Sunesis Pharmaceuticals, Inc. 55.4M 60 70 72
Underperform
58
58 50 1
Palatin Technologies, Inc. 53.2M 61 57 81
Underperform
59
59 51 1
GT Biopharma, Inc. 51.0M 60 73 75
Hold
63
63 52 1
AVANT Immunotherapeutics Inc. 46.7M 62 72 94
Hold
77
77 53 1
CASI Pharmaceuticals, Inc. 36.9M 73 62 67
Hold
64
64 54 1
Cell Genesys, Inc. 35.9M 70 84 80
Buy
82
82 55 1
Lisata Therapeutics, Inc. 34.2M 68 70 73
Hold
66
66 56 1
AIkido Pharma Inc. 33.1M 81 61 81
Hold
73
73 57 1
AIM ImmunoTech Inc. 27.9M 75 63 71
Hold
67
67 58 1
RegeneRx Biopharmaceuticals, Inc. 23.0M 72 55 76
Hold
64
64 59 1
Soligenix, Inc. 21.2M 61 63 73
Underperform
59
59 60 1
Idera Pharmaceuticals, Inc. 19.6M 65 79 83
Hold
71
71 61 1
HepaLife Technologies Inc. 19.3M 67 80 79
Buy
82
82 62 1
Enzon Pharmaceuticals, Inc. 18.6M 72 62 59
Hold
61
61 63 1
Athersys, Inc. 18.4M 50 82 76
Hold
60
60 64 1
Abeona Therapeutics Inc. 17.9M 55 85 78
Hold
65
65 65 1
Cyclacel Pharmaceuticals, Inc. 15.8M 56 74 60
Underperform
56
56 66 1
Vical Incorporated 15.4M 68 81 54
Hold
66
66 67 1
AmpliPhi Biosciences Corporation 13.4M 52 66 81
Underperform
57
57 68 1
Plus Therapeutics, Inc. 12.8M 58 54 70
Underperform
52
52 69 1
Imunon, Inc. 11.8M 78 60 74
Hold
69
69 70 1
Sonus Pharmaceuticals Inc. 10.4M 53 82 59
Hold
64
64 71 1
Windtree Therapeutics, Inc. 9.6M 54 84 75
Hold
64
64 72 1
Navidea Biopharmaceuticals, Inc. 7.5M 58 62 79
Underperform
59
59 73 1
NeoPharm, Inc. 7.4M 66 87 74
Hold
77
77 74 1
SyntheMed, Inc. 7.0M 64 66 75
Hold
62
62 75 1
NovelStem International Corp. 6.7M 92 80 47
Buy
80
80 76 1
Telik Inc. 6.4M 57 78 67
Hold
68
68 77 1
Senetek plc 6.1M 82 61 70
Hold
72
72 78 1
Capstone Therapeutics Corp. 5.8M 72 51 84
Underperform
60
60 79 1
Dendreon Corporation 5.0M 59 70 73
Hold
61
61 80 1
LadRx Corporation 4.8M 55 54 81
Underperform
56
56 81 1
Mateon Therapeutics, Inc. 3.8M 57 68 86
Hold
62
62 82 1
Marina Biotech, Inc. 3.0M 61 53 87
Hold
61
61 83 1
Oscient Pharmaceuticals Corp. 1.4M 60 62 78
Hold
60
60 84 1
Northfield Laboratories Inc. 1.2M 57 53 67
Underperform
51
51 85 1
Genta Incorporated 596.0K 76 79 82
Buy
80
80 86 1
W World Corp. 587.5K 73 68 57
Hold
66
66 87 1
Biopure Corporation 476.5K 49 76 95
Hold
69
69 88 1
Savient Pharmaceuticals, Inc. 135.6K 50 77 93
Hold
71
71 89 1
AVAX Technologies, Inc. 68.9K 59 68 90
Hold
71
71 90 1
Orchestra Therapeutics, Inc. 58.1K 49 59 94
Hold
66
66 91 1
Protein Polymer Technologies Inc. 56.5K 74 77 67
Hold
77
77 92 1
Large Scale Biology Corp. 12.9K 51 64 82
Hold
68
68 93 1
Neurobiological Technologies, Inc. 2.7K 76 89 77
Buy
80
80 94 1
9342-8530 Québec Inc. 43.0 64 58 63
Hold
61
61 95 1
ReGen Biologics Inc. 25.0 56 48 82
Underperform
56
56 96 1
Poniard Pharmaceuticals, Inc. 1.0 56 87 83
Hold
74
74 97 1

Macro Environment

Neutral
69

Typically, the stock market in United States will react to recent economic events, as well as be influenced by the sentiment in other major economies around the world. Our assessment is that these two events may influence global market sentiment. On the negative side we have the consumer price index and future intrest rates, and on the positive side we have the labor market.

Positive Labor market

A positive sign in the economy right now is the labor market. Employers have added nearly six million jobs in the past year, and unemployment has matched a 50-year low. The unemployment rate is used as a measure of the economy's health as a high employment rate is generally considered to have a positive effect on a country's GDP.

Negative Consumer price index and future intrest rates

Many investors were surprised by the high CPI numbers in the US, resulting in a strengthening dollar index, since interest rates are expected to continue to rise at an even steeper pace than expected. In light of the fact that many companies sell their goods and services outside the US, the strengthening of the dollar could be a difficult headwind for them. The exchange rate losses will continue to occur if the dollar continues to strengthen, with the continuation of hot data from the American economy as well as the Fed's hawkish tone and the continuation of interest rate increases.

Besides the events we mentioned, there are also specific events related to the Pharmaceuticals, Biotechnology & Life Sciences industry of which United Therapeutics Corporation is a part. As a result, we believe that the rising inflation may cloud the sector's shares in the near time future.

Negative Rising inflation

The sudden increase in inflation is generally regarded as the most painful since it takes companies several quarters to pass on higher input costs to consumers. Historically, companies traded in the Pharmaceuticals, Biotechnology & Life Sciences industry have been hit by high inflation times due to increased operating expenses and decreased revenues.

In considering the current macro environment and the risks that might affect United Therapeutics Corporation stock, we came to the conclusion that recent events aren't likely to affect the company's performance in the short term, and thus rated United Therapeutics Corporation macro environment with the score of 69.

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. United Therapeutics's stock is now priced above its 200-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a positive setup in the long-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), United Therapeutics's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 52.

Bearish 52
Close Price 205.89
52W Low 166.16
52W High 244.17
5D MA 206.07
50D MA 220.97
200D MA 205.81
MACD -4.62
RSI 57.44
STOCH 12.69

Balance Sheet Analysis

While the critical metrics for United Therapeutics's balance sheet were not overwhelmingly positive, nonetheless, United Therapeutics's leadership seems to be consistently making smart decisions related to managing their balance sheet. The company's assets section could set high expectations for United Therapeutics's future attractiveness, as they went to 5.4B, which is a 3.7% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. The company's asset component, therefore, received a grade of 76. Also, United Therapeutics's price to book ratio (P/B) was reported as 1.9 and represents -21.0% change from the previous report. Their industry-leading book value factors momentum reinforces an expectation for future positive momentum for their stock price going forward. The company's book value factors component, therefore, received a grade of 74. However, one concerning metric, Equity, stood out. United Therapeutics management produced disappointing equity metrics this period, which stood at 4.2B, representing a 5.5% change. This parameter often affects companies in the same industry and market capitalization by up to 9.6%. This performance is significantly less impressive than its peers and competitors. Its equity movement component, therefore, received a grade of 52. their balance sheet, therefore, earned a score of 74.

Parameter Value Change Score
Assets 5.4B 3.7% 76
Liabilities 1.2B -2.2% 62
Price to Book 1.9 -21.0% 74
Cash & Equivalents 813.3M -9.1% 59
Equity 4.2B 5.5% 52
* All values are TTM

The below chart describes United Therapeutics's performance as reflected on its balance sheet with respect to its peers. While United Therapeutics received a balance sheet score of 74, the average of its peers stands on 67.

  •  UTHR
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 120.9B 64.0 81.0 56.0 51.0 79.0 80 0 1
Gilead Sciences, Inc. 78.5B 76.0 83.0 88.0 84.0 81.0 97 1 1
Regeneron Pharmaceuticals, Inc. 74.3B 64.0 79.0 91.0 75.0 80.0 90 2 1
Vertex Pharmaceuticals Incorporated 73.0B 75.0 76.0 51.0 85.0 88.0 86 3 1
Biogen Inc. 28.7B 80.0 79.0 91.0 94.0 85.0 99 4 1
Seagen Inc. 25.0B 71.0 73.0 57.0 92.0 69.0 75 5 1
BioMarin Pharmaceutical Inc. 15.5B 60.0 79.0 53.0 76.0 85.0 82 6 1
Incyte Corporation 14.8B 67.0 77.0 48.0 81.0 83.0 81 7 1
Neurocrine Biosciences, Inc. 9.7B 87.0 83.0 60.0 42.0 83.0 90 8 1
Sarepta Therapeutics, Inc. 9.5B 80.0 72.0 63.0 46.0 59.0 70 9 1
Ionis Pharmaceuticals, Inc. 6.0B 81.0 72.0 62.0 67.0 59.0 72 10 1
Exelixis, Inc. 5.1B 60.0 63.0 50.0 57.0 78.0 66 11 1
Cytokinetics, Incorporated 4.6B 71.0 77.0 41.0 52.0 67.0 70 12 1
Mirati Therapeutics, Inc. 3.8B 62.0 67.0 59.0 58.0 58.0 63 13 1
Alkermes plc 3.6B 61.0 82.0 48.0 61.0 70.0 75 14 1
Arrowhead Pharmaceuticals, Inc. 3.3B 47.0 69.0 59.0 94.0 75.0 71 15 1
Insmed Incorporated 2.6B 57.0 67.0 54.0 51.0 58.0 58 16 1
BioCryst Pharmaceuticals, Inc. 2.3B 78.0 73.0 58.0 45.0 57.0 68 17 1
Ironwood Pharmaceuticals, Inc. 1.6B 55.0 65.0 89.0 54.0 80.0 77 18 1
Novavax, Inc. 1.6B 50.0 68.0 62.0 58.0 37.0 50 19 1
Myriad Genetics, Inc. 1.5B 56.0 60.0 52.0 43.0 66.0 56 20 1
FibroGen, Inc. 1.2B 58.0 82.0 52.0 61.0 58.0 69 21 1
Enanta Pharmaceuticals, Inc. 1.1B 51.0 66.0 64.0 45.0 60.0 60 22 1
ImmunoGen, Inc. 1.0B 71.0 66.0 63.0 55.0 58.0 64 23 1
Geron Corporation 865.2M 70.0 77.0 57.0 97.0 97.0 92 24 1
Lexicon Pharmaceuticals, Inc. 469.0M 41.0 64.0 43.0 41.0 53.0 47 25 1
Inovio Pharmaceuticals, Inc. 438.9M 79.0 75.0 43.0 46.0 49.0 62 26 1
bluebird bio, Inc. 420.3M 50.0 55.0 44.0 46.0 54.0 44 27 1
Anika Therapeutics, Inc. 345.0M 57.0 70.0 50.0 70.0 62.0 63 28 1
Rigel Pharmaceuticals, Inc. 198.8M 82.0 69.0 54.0 76.0 76.0 71 29 1
Nabi Biopharmaceuticals Inc. 47.5M 57.0 74.0 54.0 68.0 67.0 61 30 1
Acorda Therapeutics, Inc. 7.1M 68.0 61.0 39.0 49.0 45.0 49 31 1
Exact Sciences Corporation 5.7B 55.0 59.0 48.0 85.0 53.0 52 32 1
Abgenix Inc. 2.1B 80.0 51.0 85.0 92.0 45.0 66 33 1
Ligand Pharmaceuticals Incorporated 1.4B 99.0 60.0 58.0 38.0 73.0 71 34 1
Avid Bioservices, Inc. 1.1B 79.0 65.0 47.0 62.0 85.0 75 35 1
CTI BioPharma Corp. 660.0M 54.0 75.0 39.0 45.0 78.0 69 36 1
Heron Therapeutics, Inc. 477.4M 77.0 66.0 60.0 55.0 37.0 55 37 1
Organogenesis Holdings Inc. 421.5M 76.0 75.0 42.0 77.0 70.0 74 38 1
Silence Therapeutics plc 285.3M 65.0 74.0 44.0 85.0 71.0 73 39 1
XOMA Corporation 196.4M 67.0 71.0 59.0 72.0 72.0 73 40 1
Lineage Cell Therapeutics, Inc. 193.5M 45.0 62.0 63.0 91.0 65.0 67 41 1
StemCells Inc. 187.3M 65.0 64.0 49.0 41.0 95.0 60 42 1
Anixa Biosciences, Inc. 162.5M 88.0 70.0 56.0 63.0 68.0 70 43 1
CEL-SCI Corporation 150.9M 53.0 64.0 60.0 57.0 51.0 61 44 1
eXegenics Inc. 129.4M 89.0 66.0 42.0 74.0 60.0 54 45 1
iBio, Inc. 69.7M 70.0 67.0 58.0 60.0 55.0 65 46 1
Trimeris Inc 68.8M 42.0 79.0 82.0 79.0 77.0 81 47 1
Curis, Inc. 64.3M 75.0 68.0 56.0 95.0 54.0 67 48 1
ImmuCell Corporation 58.6M 63.0 66.0 65.0 71.0 73.0 72 49 1
Sunesis Pharmaceuticals, Inc. 55.4M 50.0 65.0 66.0 48.0 41.0 60 50 1
Palatin Technologies, Inc. 53.2M 91.0 67.0 54.0 54.0 43.0 61 51 1
GT Biopharma, Inc. 51.0M 48.0 69.0 48.0 50.0 61.0 60 52 1
AVANT Immunotherapeutics Inc. 46.7M 63.0 71.0 77.0 81.0 38.0 62 53 1
CASI Pharmaceuticals, Inc. 36.9M 53.0 60.0 87.0 45.0 62.0 73 54 1
Cell Genesys, Inc. 35.9M 41.0 69.0 42.0 39.0 97.0 70 55 1
Lisata Therapeutics, Inc. 34.2M 86.0 59.0 61.0 96.0 67.0 68 56 1
AIkido Pharma Inc. 33.1M 50.0 63.0 92.0 53.0 74.0 81 57 1
AIM ImmunoTech Inc. 27.9M 97.0 68.0 66.0 87.0 64.0 75 58 1
RegeneRx Biopharmaceuticals, Inc. 23.0M 71.0 66.0 76.0 52.0 55.0 72 59 1
Soligenix, Inc. 21.2M 67.0 68.0 56.0 64.0 41.0 61 60 1
Idera Pharmaceuticals, Inc. 19.6M 89.0 69.0 57.0 63.0 48.0 65 61 1
HepaLife Technologies Inc. 19.3M 73.0 72.0 72.0 77.0 46.0 67 62 1
Enzon Pharmaceuticals, Inc. 18.6M 49.0 70.0 75.0 76.0 48.0 72 63 1
Athersys, Inc. 18.4M 76.0 63.0 40.0 44.0 44.0 50 64 1
Abeona Therapeutics Inc. 17.9M 75.0 65.0 47.0 38.0 47.0 55 65 1
Cyclacel Pharmaceuticals, Inc. 15.8M 43.0 67.0 41.0 76.0 51.0 56 66 1
Vical Incorporated 15.4M 37.0 70.0 64.0 68.0 62.0 68 67 1
AmpliPhi Biosciences Corporation 13.4M 88.0 66.0 46.0 47.0 40.0 52 68 1
Plus Therapeutics, Inc. 12.8M 87.0 67.0 46.0 61.0 46.0 58 69 1
Imunon, Inc. 11.8M 68.0 70.0 82.0 72.0 54.0 78 70 1
Sonus Pharmaceuticals Inc. 10.4M 41.0 70.0 58.0 40.0 52.0 53 71 1
Windtree Therapeutics, Inc. 9.6M 68.0 67.0 43.0 50.0 45.0 54 72 1
Navidea Biopharmaceuticals, Inc. 7.5M 86.0 63.0 60.0 38.0 38.0 58 73 1
NeoPharm, Inc. 7.4M 98.0 65.0 62.0 42.0 56.0 66 74 1
SyntheMed, Inc. 7.0M 74.0 69.0 49.0 68.0 49.0 64 75 1
NovelStem International Corp. 6.7M 73.0 72.0 81.0 92.0 91.0 92 76 1
Telik Inc. 6.4M 51.0 73.0 56.0 77.0 51.0 57 77 1
Senetek plc 6.1M 48.0 67.0 79.0 62.0 78.0 82 78 1
Capstone Therapeutics Corp. 5.8M 56.0 69.0 75.0 59.0 42.0 72 79 1
Dendreon Corporation 5.0M 70.0 68.0 49.0 71.0 68.0 59 80 1
LadRx Corporation 4.8M 90.0 65.0 60.0 38.0 37.0 55 81 1
Mateon Therapeutics, Inc. 3.8M 75.0 63.0 50.0 41.0 70.0 57 82 1
Marina Biotech, Inc. 3.0M 49.0 57.0 57.0 43.0 93.0 61 83 1
Oscient Pharmaceuticals Corp. 1.4M 66.0 61.0 61.0 85.0 51.0 60 84 1
Northfield Laboratories Inc. 1.2M 91.0 66.0 49.0 45.0 51.0 57 85 1
Genta Incorporated 596.0K 47.0 75.0 52.0 81.0 97.0 76 86 1
W World Corp. 587.5K 41.0 72.0 51.0 67.0 87.0 73 87 1
Biopure Corporation 476.5K 50.0 67.0 43.0 42.0 50.0 49 88 1
Savient Pharmaceuticals, Inc. 135.6K 61.0 68.0 55.0 77.0 45.0 50 89 1
AVAX Technologies, Inc. 68.9K 72.0 67.0 46.0 45.0 69.0 59 90 1
Orchestra Therapeutics, Inc. 58.1K 54.0 69.0 46.0 40.0 49.0 49 91 1
Protein Polymer Technologies Inc. 56.5K 74.0 96.0 52.0 52.0 46.0 74 92 1
Large Scale Biology Corp. 12.9K 70.0 65.0 71.0 57.0 49.0 51 93 1
Neurobiological Technologies, Inc. 2.7K 63.0 65.0 63.0 56.0 89.0 76 94 1
9342-8530 Québec Inc. 43.0 57.0 75.0 66.0 63.0 53.0 64 95 1
ReGen Biologics Inc. 25.0 68.0 69.0 59.0 38.0 38.0 56 96 1
Poniard Pharmaceuticals, Inc. 1.0 69.0 68.0 55.0 45.0 53.0 56 97 1

Income Statement Analysis

United Therapeutics seems to be balancing strong EBITDA and Revenue Efficiency along with an overall impressive positive income statement. United Therapeutics's management was effective in improving its EBIDTA, which now sits at 962.8M and represents a 30.0% change from the last reporting period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 23.9%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. Therefore, its EBITDA component earned a score of 92. However, one discouraging result, Return Factors, stood out. United Therapeutics's reported return on equity (ROE) ratio was 18.0, representing a change of 39.4%. This metric might have a 4.1 percent impact on companies in the same industry and with the same market capitalization. These numbers show that management has been unsuccessful in fostering appropriate growth related to return on assets and return on equity momentum relative to their peers. Its return factors (ROA & ROE) components, therefore, received a grade of 53. Because its management is doing an excellent job managing these critical metrics, the income statement was given a score of 82.

Parameter Value Change Score
EBITDA 962.8M 30.0% 92
Total Revenues 1.8B 4.9% 56
Return on Equity 18.0 39.4% 53
* All values are TTM

The below chart describes United Therapeutics's performance as reflected on its income statement with respect to its peers. While United Therapeutics received a income statement score of 82 , the average of its peers stands on 67.

  •  UTHR
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 120.9B 78.0 75.0 58.0 78 0 1
Gilead Sciences, Inc. 78.5B 79.0 71.0 62.0 75 1 1
Regeneron Pharmaceuticals, Inc. 74.3B 97.0 48.0 82.0 67 2 1
Vertex Pharmaceuticals Incorporated 73.0B 54.0 84.0 64.0 78 3 1
Biogen Inc. 28.7B 89.0 63.0 74.0 74 4 1
Seagen Inc. 25.0B 51.0 59.0 70.0 60 5 1
BioMarin Pharmaceutical Inc. 15.5B 70.0 93.0 51.0 88 6 1
Incyte Corporation 14.8B 51.0 91.0 50.0 80 7 1
Neurocrine Biosciences, Inc. 9.7B 49.0 62.0 66.0 60 8 1
Sarepta Therapeutics, Inc. 9.5B 47.0 54.0 72.0 54 9 1
Ionis Pharmaceuticals, Inc. 6.0B 74.0 44.0 85.0 58 10 1
Exelixis, Inc. 5.1B 67.0 56.0 79.0 64 11 1
Cytokinetics, Incorporated 4.6B 37.0 92.0 46.0 76 12 1
Mirati Therapeutics, Inc. 3.8B 49.0 66.0 72.0 65 13 1
Alkermes plc 3.6B 90.0 43.0 86.0 62 14 1
Arrowhead Pharmaceuticals, Inc. 3.3B 93.0 45.0 82.0 64 15 1
Insmed Incorporated 2.6B 46.0 63.0 54.0 58 16 1
BioCryst Pharmaceuticals, Inc. 2.3B 48.0 66.0 68.0 63 17 1
Ironwood Pharmaceuticals, Inc. 1.6B 89.0 65.0 76.0 76 18 1
Novavax, Inc. 1.6B 95.0 45.0 71.0 62 19 1
Myriad Genetics, Inc. 1.5B 88.0 51.0 55.0 62 20 1
FibroGen, Inc. 1.2B 68.0 93.0 45.0 85 21 1
Enanta Pharmaceuticals, Inc. 1.1B 90.0 77.0 66.0 84 22 1
ImmunoGen, Inc. 1.0B 91.0 45.0 83.0 64 23 1
Geron Corporation 865.2M 90.0 73.0 56.0 79 24 1
Lexicon Pharmaceuticals, Inc. 469.0M 99.0 62.0 77.0 77 25 1
Inovio Pharmaceuticals, Inc. 438.9M 39.0 59.0 73.0 57 26 1
bluebird bio, Inc. 420.3M 40.0 83.0 60.0 73 27 1
Anika Therapeutics, Inc. 345.0M 72.0 46.0 85.0 59 28 1
Rigel Pharmaceuticals, Inc. 198.8M 87.0 67.0 76.0 69 29 1
Nabi Biopharmaceuticals Inc. 47.5M 37.0 88.0 77.0 86 30 1
Acorda Therapeutics, Inc. 7.1M 47.0 87.0 69.0 85 31 1
Exact Sciences Corporation 5.7B 56.0 66.0 68.0 66 32 1
Abgenix Inc. 2.1B 47.0 47.0 46.0 46 33 1
Ligand Pharmaceuticals Incorporated 1.4B 96.0 53.0 83.0 71 34 1
Avid Bioservices, Inc. 1.1B 55.0 53.0 90.0 60 35 1
CTI BioPharma Corp. 660.0M 37.0 88.0 40.0 72 36 1
Heron Therapeutics, Inc. 477.4M 53.0 82.0 44.0 72 37 1
Organogenesis Holdings Inc. 421.5M 86.0 59.0 78.0 72 38 1
Silence Therapeutics plc 285.3M 38.0 72.0 62.0 64 39 1
XOMA Corporation 196.4M 67.0 52.0 56.0 53 40 1
Lineage Cell Therapeutics, Inc. 193.5M 97.0 71.0 76.0 73 41 1
StemCells Inc. 187.3M 49.0 91.0 79.0 89 42 1
Anixa Biosciences, Inc. 162.5M 59.0 86.0 82.0 85 43 1
CEL-SCI Corporation 150.9M 59.0 79.0 90.0 80 44 1
eXegenics Inc. 129.4M 75.0 52.0 63.0 56 45 1
iBio, Inc. 69.7M 96.0 48.0 49.0 51 46 1
Trimeris Inc 68.8M 67.0 54.0 64.0 57 47 1
Curis, Inc. 64.3M 69.0 53.0 51.0 54 48 1
ImmuCell Corporation 58.6M 46.0 43.0 39.0 43 49 1
Sunesis Pharmaceuticals, Inc. 55.4M 37.0 74.0 58.0 70 50 1
Palatin Technologies, Inc. 53.2M 97.0 56.0 44.0 57 51 1
GT Biopharma, Inc. 51.0M 59.0 72.0 89.0 73 52 1
AVANT Immunotherapeutics Inc. 46.7M 41.0 77.0 67.0 72 53 1
CASI Pharmaceuticals, Inc. 36.9M 77.0 60.0 61.0 62 54 1
Cell Genesys, Inc. 35.9M 95.0 84.0 78.0 84 55 1
Lisata Therapeutics, Inc. 34.2M 59.0 71.0 64.0 70 56 1
AIkido Pharma Inc. 33.1M 59.0 61.0 53.0 61 57 1
AIM ImmunoTech Inc. 27.9M 79.0 63.0 57.0 63 58 1
RegeneRx Biopharmaceuticals, Inc. 23.0M 59.0 51.0 95.0 55 59 1
Soligenix, Inc. 21.2M 71.0 62.0 55.0 63 60 1
Idera Pharmaceuticals, Inc. 19.6M 59.0 81.0 65.0 79 61 1
HepaLife Technologies Inc. 19.3M 77.0 79.0 78.0 80 62 1
Enzon Pharmaceuticals, Inc. 18.6M 37.0 64.0 44.0 62 63 1
Athersys, Inc. 18.4M 94.0 82.0 61.0 82 64 1
Abeona Therapeutics Inc. 17.9M 94.0 85.0 64.0 85 65 1
Cyclacel Pharmaceuticals, Inc. 15.8M 59.0 75.0 59.0 74 66 1
Vical Incorporated 15.4M 37.0 86.0 80.0 81 67 1
AmpliPhi Biosciences Corporation 13.4M 59.0 67.0 63.0 66 68 1
Plus Therapeutics, Inc. 12.8M 59.0 53.0 48.0 54 69 1
Imunon, Inc. 11.8M 59.0 57.0 79.0 60 70 1
Sonus Pharmaceuticals Inc. 10.4M 97.0 82.0 56.0 82 71 1
Windtree Therapeutics, Inc. 9.6M 59.0 87.0 47.0 84 72 1
Navidea Biopharmaceuticals, Inc. 7.5M 37.0 63.0 63.0 62 73 1
NeoPharm, Inc. 7.4M 80.0 86.0 83.0 87 74 1
SyntheMed, Inc. 7.0M 44.0 68.0 64.0 66 75 1
NovelStem International Corp. 6.7M 89.0 79.0 76.0 80 76 1
Telik Inc. 6.4M 76.0 81.0 63.0 78 77 1
Senetek plc 6.1M 45.0 63.0 56.0 61 78 1
Capstone Therapeutics Corp. 5.8M 61.0 52.0 45.0 51 79 1
Dendreon Corporation 5.0M 95.0 67.0 76.0 70 80 1
LadRx Corporation 4.8M 59.0 54.0 39.0 54 81 1
Mateon Therapeutics, Inc. 3.8M 61.0 67.0 69.0 68 82 1
Marina Biotech, Inc. 3.0M 96.0 53.0 47.0 53 83 1
Oscient Pharmaceuticals Corp. 1.4M 55.0 58.0 78.0 62 84 1
Northfield Laboratories Inc. 1.2M 76.0 53.0 57.0 53 85 1
Genta Incorporated 596.0K 57.0 80.0 66.0 79 86 1
W World Corp. 587.5K 74.0 82.0 51.0 68 87 1
Biopure Corporation 476.5K 62.0 87.0 61.0 76 88 1
Savient Pharmaceuticals, Inc. 135.6K 90.0 72.0 89.0 77 89 1
AVAX Technologies, Inc. 68.9K 92.0 70.0 61.0 68 90 1
Orchestra Therapeutics, Inc. 58.1K 37.0 70.0 43.0 59 91 1
Protein Polymer Technologies Inc. 56.5K 94.0 83.0 39.0 77 92 1
Large Scale Biology Corp. 12.9K 46.0 71.0 62.0 64 93 1
Neurobiological Technologies, Inc. 2.7K 46.0 98.0 73.0 89 94 1
9342-8530 Québec Inc. 43.0 40.0 59.0 58.0 58 95 1
ReGen Biologics Inc. 25.0 44.0 52.0 58.0 48 96 1
Poniard Pharmaceuticals, Inc. 1.0 74.0 88.0 66.0 87 97 1

Cash Flow Analysis

Overall, United Therapeutics's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. United Therapeutics's management was effective in improving their net cash flow, which now sits at -19.0M and represents a -112.2% change from the previous report. Their net cash flow metrics are especially remarkable relative to their peers. The company's net cash flow, therefore, received a grade of 93. Also, Free cash flow numbers published by United Therapeutics were 14.9, which was a 40.6% change from the previous filing. This parameter could affect companies in the same industry and market capitalization by up to 1.2%. Their free cash flow situation is all the more impressive relative to their peers and competitors. Consequently, their free cash flow movement received a grade of 92. On the other hand, Capital Expenditure, jumped out as looking rather underwhelming. United Therapeutics's management did not a remarkable job this period managing capital expenditures (CapEx). In terms of the raw numbers, CapEx was reported as -123.7M, which represents a -2.4% change from the last period. This performance is all the more uninspiring relative to their peers and competitors. Its CapEx movement, therefore, received a grade of 67. Therefore, we scored its cash flow a 92.

Parameter Value Change Score
Net Cashflow -19.0M -112.2% 93
Capital Expenditure -123.7M -2.4% 67
Asset Turnover 0.4 2.6% 82
Free Cashflow Per Share 14.9 40.6% 92
* All values are TTM

The below chart describes United Therapeutics's performance as reflected on its cash flow with respect to its peers. While United Therapeutics received a cash flow score of 92, the average of its peers stands on 70.

  •  UTHR
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 120.9B 74.0 74.0 59.0 80.0 76 0 1
Gilead Sciences, Inc. 78.5B 72.0 63.0 64.0 62.0 71 1 1
Regeneron Pharmaceuticals, Inc. 74.3B 70.0 67.0 69.0 53.0 70 2 1
Vertex Pharmaceuticals Incorporated 73.0B 79.0 93.0 68.0 60.0 79 3 1
Biogen Inc. 28.7B 52.0 53.0 90.0 52.0 60 4 1
Seagen Inc. 25.0B 67.0 73.0 76.0 76.0 74 5 1
BioMarin Pharmaceutical Inc. 15.5B 59.0 50.0 63.0 74.0 63 6 1
Incyte Corporation 14.8B 66.0 81.0 96.0 74.0 77 7 1
Neurocrine Biosciences, Inc. 9.7B 94.0 90.0 50.0 78.0 89 8 1
Sarepta Therapeutics, Inc. 9.5B 86.0 51.0 52.0 77.0 81 9 1
Ionis Pharmaceuticals, Inc. 6.0B 97.0 96.0 85.0 50.0 93 10 1
Exelixis, Inc. 5.1B 61.0 46.0 89.0 52.0 65 11 1
Cytokinetics, Incorporated 4.6B 53.0 50.0 92.0 89.0 67 12 1
Mirati Therapeutics, Inc. 3.8B 59.0 59.0 94.0 83.0 71 13 1
Alkermes plc 3.6B 65.0 48.0 53.0 62.0 63 14 1
Arrowhead Pharmaceuticals, Inc. 3.3B 42.0 42.0 46.0 58.0 44 15 1
Insmed Incorporated 2.6B 75.0 63.0 84.0 50.0 75 16 1
BioCryst Pharmaceuticals, Inc. 2.3B 73.0 69.0 93.0 78.0 81 17 1
Ironwood Pharmaceuticals, Inc. 1.6B 86.0 79.0 44.0 58.0 78 18 1
Novavax, Inc. 1.6B 50.0 41.0 51.0 51.0 49 19 1
Myriad Genetics, Inc. 1.5B 55.0 45.0 37.0 68.0 54 20 1
FibroGen, Inc. 1.2B 59.0 63.0 89.0 84.0 71 21 1
Enanta Pharmaceuticals, Inc. 1.1B 62.0 73.0 90.0 81.0 74 22 1
ImmunoGen, Inc. 1.0B 61.0 62.0 48.0 78.0 63 23 1
Geron Corporation 865.2M 49.0 63.0 45.0 59.0 51 24 1
Lexicon Pharmaceuticals, Inc. 469.0M 68.0 74.0 95.0 47.0 73 25 1
Inovio Pharmaceuticals, Inc. 438.9M 73.0 84.0 41.0 79.0 72 26 1
bluebird bio, Inc. 420.3M 80.0 82.0 84.0 80.0 86 27 1
Anika Therapeutics, Inc. 345.0M 68.0 51.0 61.0 72.0 69 28 1
Rigel Pharmaceuticals, Inc. 198.8M 75.0 64.0 67.0 66.0 73 29 1
Nabi Biopharmaceuticals Inc. 47.5M 71.0 47.0 40.0 84.0 72 30 1
Acorda Therapeutics, Inc. 7.1M 70.0 50.0 67.0 61.0 64 31 1
Exact Sciences Corporation 5.7B 42.0 46.0 63.0 80.0 52 32 1
Abgenix Inc. 2.1B 61.0 53.0 45.0 61.0 57 33 1
Ligand Pharmaceuticals Incorporated 1.4B 64.0 56.0 40.0 42.0 57 34 1
Avid Bioservices, Inc. 1.1B 81.0 67.0 63.0 64.0 78 35 1
CTI BioPharma Corp. 660.0M 73.0 74.0 72.0 99.0 82 36 1
Heron Therapeutics, Inc. 477.4M 93.0 85.0 69.0 46.0 86 37 1
Organogenesis Holdings Inc. 421.5M 58.0 48.0 61.0 49.0 58 38 1
Silence Therapeutics plc 285.3M 74.0 71.0 72.0 90.0 80 39 1
XOMA Corporation 196.4M 74.0 90.0 67.0 72.0 81 40 1
Lineage Cell Therapeutics, Inc. 193.5M 89.0 39.0 52.0 40.0 69 41 1
StemCells Inc. 187.3M 74.0 58.0 96.0 93.0 90 42 1
Anixa Biosciences, Inc. 162.5M 58.0 65.0 67.0 82.0 66 43 1
CEL-SCI Corporation 150.9M 71.0 57.0 95.0 70.0 72 44 1
eXegenics Inc. 129.4M 58.0 95.0 66.0 87.0 77 45 1
iBio, Inc. 69.7M 86.0 66.0 79.0 75.0 92 46 1
Trimeris Inc 68.8M 70.0 98.0 66.0 93.0 83 47 1
Curis, Inc. 64.3M 64.0 85.0 37.0 88.0 74 48 1
ImmuCell Corporation 58.6M 62.0 94.0 57.0 74.0 74 49 1
Sunesis Pharmaceuticals, Inc. 55.4M 62.0 69.0 65.0 77.0 72 50 1
Palatin Technologies, Inc. 53.2M 81.0 63.0 50.0 94.0 81 51 1
GT Biopharma, Inc. 51.0M 83.0 57.0 67.0 64.0 75 52 1
AVANT Immunotherapeutics Inc. 46.7M 75.0 73.0 85.0 91.0 94 53 1
CASI Pharmaceuticals, Inc. 36.9M 54.0 75.0 81.0 79.0 67 54 1
Cell Genesys, Inc. 35.9M 97.0 40.0 96.0 62.0 80 55 1
Lisata Therapeutics, Inc. 34.2M 65.0 75.0 37.0 90.0 73 56 1
AIkido Pharma Inc. 33.1M 72.0 77.0 67.0 91.0 81 57 1
AIM ImmunoTech Inc. 27.9M 59.0 77.0 39.0 96.0 71 58 1
RegeneRx Biopharmaceuticals, Inc. 23.0M 62.0 87.0 67.0 87.0 76 59 1
Soligenix, Inc. 21.2M 62.0 79.0 50.0 88.0 73 60 1
Idera Pharmaceuticals, Inc. 19.6M 87.0 50.0 67.0 90.0 83 61 1
HepaLife Technologies Inc. 19.3M 72.0 73.0 69.0 85.0 79 62 1
Enzon Pharmaceuticals, Inc. 18.6M 47.0 96.0 67.0 49.0 59 63 1
Athersys, Inc. 18.4M 76.0 57.0 41.0 92.0 76 64 1
Abeona Therapeutics Inc. 17.9M 75.0 52.0 92.0 90.0 78 65 1
Cyclacel Pharmaceuticals, Inc. 15.8M 71.0 53.0 38.0 49.0 60 66 1
Vical Incorporated 15.4M 54.0 77.0 89.0 39.0 54 67 1
AmpliPhi Biosciences Corporation 13.4M 83.0 48.0 50.0 85.0 81 68 1
Plus Therapeutics, Inc. 12.8M 69.0 53.0 41.0 93.0 70 69 1
Imunon, Inc. 11.8M 68.0 89.0 56.0 62.0 74 70 1
Sonus Pharmaceuticals Inc. 10.4M 72.0 84.0 74.0 43.0 59 71 1
Windtree Therapeutics, Inc. 9.6M 69.0 53.0 95.0 88.0 75 72 1
Navidea Biopharmaceuticals, Inc. 7.5M 76.0 62.0 54.0 96.0 79 73 1
NeoPharm, Inc. 7.4M 53.0 81.0 58.0 89.0 74 74 1
SyntheMed, Inc. 7.0M 55.0 64.0 66.0 90.0 75 75 1
NovelStem International Corp. 6.7M 68.0 82.0 41.0 41.0 47 76 1
Telik Inc. 6.4M 81.0 71.0 84.0 52.0 67 77 1
Senetek plc 6.1M 75.0 89.0 65.0 58.0 70 78 1
Capstone Therapeutics Corp. 5.8M 62.0 80.0 69.0 94.0 84 79 1
Dendreon Corporation 5.0M 65.0 66.0 77.0 70.0 73 80 1
LadRx Corporation 4.8M 50.0 96.0 67.0 96.0 81 81 1
Mateon Therapeutics, Inc. 3.8M 76.0 59.0 67.0 89.0 86 82 1
Marina Biotech, Inc. 3.0M 76.0 51.0 67.0 96.0 87 83 1
Oscient Pharmaceuticals Corp. 1.4M 79.0 58.0 54.0 84.0 78 84 1
Northfield Laboratories Inc. 1.2M 68.0 51.0 40.0 90.0 67 85 1
Genta Incorporated 596.0K 78.0 91.0 57.0 90.0 82 86 1
W World Corp. 587.5K 69.0 82.0 40.0 51.0 57 87 1
Biopure Corporation 476.5K 79.0 77.0 98.0 95.0 95 88 1
Savient Pharmaceuticals, Inc. 135.6K 85.0 54.0 83.0 93.0 93 89 1
AVAX Technologies, Inc. 68.9K 79.0 73.0 81.0 92.0 90 90 1
Orchestra Therapeutics, Inc. 58.1K 84.0 91.0 85.0 93.0 94 91 1
Protein Polymer Technologies Inc. 56.5K 52.0 76.0 95.0 65.0 67 92 1
Large Scale Biology Corp. 12.9K 46.0 76.0 94.0 98.0 82 93 1
Neurobiological Technologies, Inc. 2.7K 73.0 85.0 98.0 51.0 77 94 1
9342-8530 Québec Inc. 43.0 61.0 84.0 57.0 65.0 63 95 1
ReGen Biologics Inc. 25.0 64.0 52.0 72.0 97.0 82 96 1
Poniard Pharmaceuticals, Inc. 1.0 68.0 89.0 66.0 97.0 83 97 1

This report, prepared and provided by Deshe Labs Ltd ("Deshe"), is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used, construed, or considered as financial or investment advice, an offer, a solicitation of any offer, a recommendation, or an offer to invest in, sell or buy the securities mentioned in this report or other form of a financial asset or as a marketing communication under FCA Rules. For the full disclaimer, click here.